ReviewFrontiers in cardiovascular medicine2026
Progress in research on the association between glucose metabolism disorders and intracranial and extracranial atherosclerotic stenosis.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Intracranial atherosclerotic stenosis (ICAS) and extracranial atherosclerotic stenosis (ECAS) are major vascular substrates for ischemic stroke. Existing reviews often discuss ICAS and ECAS together, overlooking their distinct pathological responses to glucose dysregulation, and lack systematic summary of the independent role of insulin resistance in normoglycemic individuals. This review aims to systematically summarize the molecular mechanisms, imaging features, clinical biomarkers, and intervention strategies by which glucose metabolism disorders (diabetes mellitus, insulin resistance, impaired glucose tolerance) promote ICAS and ECAS. Methods: This is a narrative review of relevant literature published in recent years, with no systematic meta-analysis performed. Results: Hyperglycemia and insulin resistance synergistically accelerate atherosclerosis through accumulation of advanced glycation end products (AGEs), enhanced oxidative stress, activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome, and phenotypic switching of vascular smooth muscle cells (VSMCs). Clinical studies have confirmed that hemoglobin A1c (HbA1c) ≥ 6.5% is positively correlated with anterior circulation ICAS (OR = 2.04, Conclusion: Hyperglycemia and insulin resistance accelerate intracranial and extracranial atherosclerosis via AGEs accumulation, oxidative stress, NLRP3 inflammasome activation, and VSMC phenotypic switching. HbA1c and the TyG index can serve as clinical screening tools. Key questions remain regarding whether different subtypes of glucose metabolism disorders differentially affect intracranial versus extracranial arteries, and whether early intervention in prediabetic populations reduces stroke risk. This review provides a theoretical reference for risk stratification and individualized prevention in populations at high risk of ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.